Elotuzumab (anti-SLAMF7 monoclonal antibody) in myelofibrosis
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-06-11 — Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis: Phase II trial (early-stage) launched to evaluate elotuzumab monotherapy in JAK2-mutated myelofibrosis, with endpoints including disease control, blood count improvement, and bone marrow function recovery — first investigation of anti-SLAMF7 immunotherapy in MF. (novelty: 4)
Open questions
Related
Contributing findings
Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis
11-jun-2026
novelty 4
per-area 4
introduces